Try ALLEVYN◊ LIFE for one more day
You might know patients whose wounds could benefit from a little more wear time 1 and excellent exudate management 2, active patients who you might not need to see so often. They could benefit from the ALLEVYN◊ LIFE one more day approach.
What is the one more day approach?
Frequent dressing changes can cause unnecessary disruption for nurses and their patients. Wouldn't it be better if we could do fewer changes while maintaining wound healing and comfort?
Simply identify active patients who could benefit from longer wear, who you might not need to visit so often:
- Has an active lifestyle
- Has low to moderate exudate
- Engaged in their own care
- Getting back into their real life
Try one more day and see how you can change more by changing less.
For those patients who will benefit, ALLEVYN◊ LIFE can be worn almost twice as long as standard dressings 1.
- Joy H, Bielby A, Searle R. A collaborative project to enhance efficiency through dressing change practice. Journal of wound care. 2015;24(7):312, 314-317. n=37; when used with appropriate training education and promotion of practice change.
- Smith & Nephew May 2016 2016. New ALLEVYN Life Gen2 wcl - Physical Testing. Internal Report. DS/15/025/R.
Key Features and Benefits of ALLEVYN Life Foam Dressings
- ALLEVYN Life foam dressings are longer lasting, showerproof, and comfortable 1,2,3,4
- You’ll know when it needs changing with the easy to read change indicator on the top of the foam dressing 4
- Excess fluid is reassuringly masked and the foam dressing is cushioned for comfort 3
- Helps to keep potential leaks and odour locked away for more peace of mind 3,5,6
These features mean that the foam dressing can be left on for longer, aiming to give you at least one more day between dressing changes.
Patient Information for ALLEVYN LIFE™
Why ALLEVYN LIFE™ has been recommended for you ALLEVYN LIFE has been specifically designed to provide you with an optimal experience in the healing of your wound. Each dressing is designed to enable you to carry out your daily activities and help manage your budget.
- ALLEVYN LIFE is comfortable, secure and conforms to your body shape enabling you to carry out your daily activities.
- ALLEVYN LIFE can be left on the wound for up to 7 days,1 depending on how much fluid is draining from your wound. This will minimise wastage1,2 and your need for clinic visits. Each dressing change has a cost and ALLEVYN LIFE will help manage your budget directly with reduced nursing visits and dressing changes.3
- Allevyn LIFE has a gentle yet strong adhesive. The dressing will feel secure, yet the gentle adhesive will minimise pain and discomfort when it comes time for the dressing to be removed4.
- ALLEVYN LIFE cushions the wound and surrounding skin, protecting your wound from every day knocks and bumps.
- ALLEVYN LIFE has a masking layer to reduce the visibility of fluid that usually oozes from the wound into the dressing.5 You can feel confident in the look of the dressing. Only when the fluid stain extends past the masking layer is it time to change the dressing. This ‘change indicator’ feature reduces the need for more frequent dressing changes making your dollar go further.
- ALLEVYN LIFE also masks wound odour6 thereby avoiding unnecessary embarrassment as you carry out your daily activities.
1. Dharma H. Multi-centre, non-comparative clinical in market evaluation of ALLEVYN gentle border dressing. Data on file; 2008:report OR-DOF/011.
2. Simon D, Bielby A. A structured collaborative approach to appraise the clinical performance of a new product. Wounds UK 2014; 10:80-97.
3. Joy H et al. A collaborative project to enhance efficiency through dressing change practice. Journal of Woundcare 2015 ; 24 (7):312-317.
4. Hurd T et al. A multi-centre in-market evaluation of ALLEVYN gentle border, Wounds UK, 2009, Vol 5, No3.
5. Roberts S. Simulated wound model testing of ALLEVYN LIFE and Mepilex Border. Data on file report; June 2012: report DS/12/129/DOF.
6. Roberts S. Odour reducing properties of ALLEVYN LIFE. Data on file; 2012: report DS/12/127/DOF.